Analysis of the clinical efficacy of pirfenidone (Aisri) and the actual treatment effect of patients

Pirfenidone (Pirfenidone) is an oral anti-fibrotic drug mainly used for the treatment of patients with idiopathic pulmonary fibrosis (IPF). It slows down the fibrosis process of lung tissue by inhibiting fibrosis-related cytokines such as TGF-β and collagen synthesis, thereby improving the rate of lung function decline. Clinical studies have shown that pirfenidone can significantly delay the decline of lung function, improve patients' quality of life, and extend progression-free survival.

In clinical trials, pirfenidone has a relatively obvious protective effect on lung function. Multiple randomized controlled studies have shown that the annual decline in vital capacity of IPF patients treated with pirfenidone is significantly lower than that of the placebo group, especially among patients who took the drug early. At the same time, the drug can also relieve symptoms such as dyspnea and fatigue to a certain extent, and improve the patient's daily living ability.

Judging from actual treatment feedback from patients, the vast majority of patients can feel their symptoms improve or their condition stabilize after continuous use for 3–6 months, but some patients may experience mild to moderate side effects, such as nausea, rash or gastrointestinal discomfort. Through reasonable dose adjustment and follow-up management, most side effects can be controlled without affecting continued medication, thereby ensuring the continuity of the therapeutic effect.

Overall, pirfenidone has certain clinical value in delaying the progression of idiopathic pulmonary fibrosis, improving the rate of decline in lung function, and improving quality of life. During use, patients need to adhere to regular medication, regularly review lung function, liver and kidney function, and adjust the dosage under the guidance of a doctor to ensure maximum drug efficacy and reduce the risk of potential side effects.

Reference materials:https://www.drugs.com/